Diarrhea-Predominant Irritable Bowel Syndrome

Treatment with once-daily linaclotide was well-tolerated and resulted in significant improvement in spontaneous bowel movements and stool consistency vs. placebo among children with functional constipation, researchers reported.

Titrated low-dose amitriptyline demonstrated effectiveness and tolerability as a second-line therapy for irritable bowel syndrome in primary care compared with placebo, a randomized study in the United Kingdom showed.

Parallel, a prescription digital therapeutic developed by Mahana Therapeutics for the treatment of irritable bowel syndrome, received marketing authorization from the FDA, according to a company press release.

RHB-102 was safe and improved stool consistency in patients with diarrhea-predominant irritable bowel syndrome, or IBS-D, according to a recent study. It was the top story in gastroenterology last week.

In men and women with diarrhea-predominant irritable bowel syndrome, RHB-102 was an effective and safe treatment, according to the American Journal of Gastroenterology.

Children with celiac disease have a higher risk for irritable bowel syndrome and functional constipation even if they adhere to a gluten-free diet, according to study results.

An investigational, bimodal release ondansetron tablet improved stool consistency in patients with diarrhea-predominant irritable bowel syndrome, according to study results.

In this exclusive video, Gregory S. Sayuk, MD, MPH, of the division of gastroenterology at Washington University School of Medicine in St. Louis, discusses how providers and patients have adapted to changes implemented in gastroenterology practices in response to the COVID-19 pandemic.

According to a systematic review and network analysis published in Gut, several psychological therapies were efficacious for treatment of irritable bowel syndrome; however, none were better compared with another.

In this exclusive video perspective from the GUILD Conference 2020, Lin Chang, MD, from the David Geffen School of Medicine at the University of California, Los Angeles, discusses her presentation on updates in irritable bowel syndrome.